Cart
sales@molnova.com
HDAC6-IN-9
CAS No. 2796282-58-9
HDAC6-IN-9( —— )
Catalog No. M35480 CAS No. 2796282-58-9
HDAC6-IN-9 is an orally active and highly effective γ-secretase modulator that can significantly reduce the level of Aβ42 in mouse brain and can be used to study neurological diseases.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 686 | In Stock |
|
| 10MG | 938 | In Stock |
|
| 25MG | 1444 | In Stock |
|
| 50MG | 1841 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameHDAC6-IN-9
-
NoteResearch use only, not for human use.
-
Brief DescriptionHDAC6-IN-9 is an orally active and highly effective γ-secretase modulator that can significantly reduce the level of Aβ42 in mouse brain and can be used to study neurological diseases.
-
DescriptionHDAC6-IN-9 (compound 12c) is a potent and selective HDAC6 inhibitor with IC50 values of 11.8, 15.2, 4.2, 139.6, 21.3 nM for HDAC1,HDAC3, HDAC6, HDAC8, HDAC10, respectively. HDAC6-IN-9 shows anti-proliferative activities.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayNeuroscience
-
TargetGamma-secretase
-
RecptorGamma-secretase
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2796282-58-9
-
Formula Weight320.34
-
Molecular FormulaC19H16N2O3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C(NO)C1=CC=C(C=C1)CC(=O)NC=2C=CC=3C=CC=CC3C2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Li X,et al. Design, Synthesis, and biological evaluation of HDAC6 inhibitors based on Cap modification strategy. Bioorg Chem. 2022 Aug;125:105874.?
molnova catalog
related products
-
Brontictuzumab
Brontictuzumab (OMP 52M5) is a monoclonal antibody that targets Notch1 and inhibits activation of the pathway.
-
CB-103
CB-103 is a orally active inhibitor of notch signaling pathway, with anti-tumor activity. CB-103 has shown the ability to block NOTCH signaling in human T cell acute lymphoblastic leukemia cancer cell lines, and?exhibits anti-tumor efficacy in GSI resistant T-ALL cell lines.
-
Enoticumab
Enoticumab (REGN421) is a fully human IgG1 monoclonal antibody with anticancer activity that inhibits the growth of cancer cells.Enoticumab binds human Dll4 and disrupts Notch-mediated signaling.
